PARP1 and breast cancer: The aim of this review is to summarize the mechanisms of action and current clinical evidence supporting the antitumor activity of poly (ADP-ribose) polymerase (PARP) inhibitors in ovarian and breast cancers with defects in the repair of DNA damage, related or unrelated to BRCA mutations.